Quintrio
Home

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Kalaris Therapeutics, Inc. Common Stock

KLRS

Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor VEGF drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.

Last trade $1.38
Day change -$0.08 (-5.48%)
Day range $1.37 – $1.48
Volume 175,445
Market cap $35M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$34.76M
Price / earnings
—
Price / book
0.73×
Price / sales
—
EV / sales
—
EV / EBITDA
0.27×

Profitability

Earnings per share
-$1.82
Return on assets
-48.76%
Return on equity
-91.55%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
10×
Quick ratio
10×
Cash ratio
5.57×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$40.26M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for KLRS, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025
Revenue$0$0$0$0$0$0$0
Cost of revenue$0$0$0$0$0$0$0
Gross profit$0$0$0$0$0$0$0
Selling, general and administrative$3.47M$3.37M$4.26M$3.64M$3.62M$3.82M$4.32M
Research and development$8.34M$9.02M$7.57M$7.16M$9.13M$8.44M$6.03M
Total operating expenses$11.81M$12.39M$11.83M$10.8M$12.74M$12.26M$10.35M
Operating income-$11.81M-$12.39M-$11.83M-$10.8M-$12.74M-$12.26M-$10.35M
Interest expense$0$0$0$0$0$0-$1.44M
Income before taxes-$11.03M-$11.52M-$10.86M-$10M-$11.89M-$11.35M-$10.2M
Income taxes$0$0$0$0$0$0$0
Net income-$11.03M-$11.52M-$10.86M-$10M-$11.89M-$11.35M-$10.2M
Net income attributable to common shareholders-$11.03M-$11.52M-$10.86M-$10M-$11.89M-$11.35M-$10.2M
EBITDA-$11.8M-$12.38M-$11.82M-$10.79M-$12.74M-$12.26M-$10.35M
Basic earnings per share-$0.46-$0.48-$0.46-$0.51-$0.64-$0.61-$2.52
Diluted earnings per share-$0.46-$0.48-$0.46-$0.51-$0.64-$0.61-$2.52

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Kalaris to Present at Morgan Stanley 24th Annual Global Healthcare Conference

Kalaris Therapeutics (Nasdaq: KLRS), a clinical-stage biopharmaceutical company, announced that management will participate in a Fireside Chat at the Morgan Stanley 24th Annual Global Healthcare Conference on September 15, 2026. The company is developing TH103, a dual-action anti-VEGF therapeutic, currently in Phase 1b/2 trials for neovascular Age-related Macular Degeneration (nAMD), with preliminary data expected in the first half of 2027.

GlobeNewswire Inc.

SDEV: Abbott Cooper PLLC Announces Investigation on Behalf of Stablecoin Development Corporation (Formerly Novabay Pharmaceuticals, Inc.) Stockholders

Abbott Cooper PLLC is investigating potential fiduciary duty breaches by the board of directors of Stablecoin Development Corporation (formerly NovaBay Pharmaceuticals, Inc.). The investigation targets stockholders who continuously held shares since prior to August 19, 2025. Similar investigations are also underway for Kalaris Therapeutics (formerly AlloVir) and Abundia Global Impact Group (formerly Houston American Energy Corp.).

GlobeNewswire Inc.

Kalaris Therapeutics Reports Positive TH103 Phase 1a SAD Results from Expanded Neovascular AMD Cohorts

Kalaris Therapeutics announced positive Phase 1a data for TH103, its investigational treatment for neovascular AMD. The expanded trial of 17 treatment-naive patients showed improvements in vision and retinal anatomy, with 29% requiring no additional anti-VEGF treatment during six-month follow-up. TH103 demonstrated 27-53 fold lower plasma levels compared to leading anti-VEGF agents while maintaining efficacy. The company is actively enrolling patients in Phase 1b/2 trials with preliminary data expected in H1 2027.

GlobeNewswire Inc.

Kalaris Announces Upcoming Presentation of TH103 Phase 1a Clinical Data at American Society of Retina Specialists; Ph 1b/2 Clinical Trial Actively Enrolling

Kalaris Therapeutics announced it will present Phase 1a clinical data for TH103, a novel dual-targeting VEGF/HSPG biologic, at the American Society of Retina Specialists 2026 Annual Meeting on July 17, 2026. The company's Phase 1b/2 multiple ascending dose study for neovascular age-related macular degeneration is actively enrolling patients, with initial data expected in the first half of 2027.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.